{"transactions":[{"id":4634641,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:19:54.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":9727,"price":2.18,"value":21204.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026."}],"balance_after":43059,"source":{"system":"sec-edgar","filing":"0001628280-26-064317","document":"wk-form4_1790889591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000162828026064317/wk-form4_1790889591.xml","form_type":"4"}},{"id":912081,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-11T02:10:49.000Z","date":"2026-02-09","kind":"sale","planned":false,"acquired":false,"shares":335,"price":2.3929,"value":801.6215,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":33332,"source":{"system":"sec-edgar","filing":"0001838041-26-000004","document":"wk-form4_1770775846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804126000004/wk-form4_1770775846.xml","form_type":"4"}},{"id":912080,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-11T02:10:49.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":2962,"price":2.4297,"value":7196.7714,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":33667,"source":{"system":"sec-edgar","filing":"0001838041-26-000004","document":"wk-form4_1770775846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804126000004/wk-form4_1770775846.xml","form_type":"4"}},{"id":942151,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:34:52.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":365000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":365000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":365000},"source":{"system":"sec-edgar","filing":"0001838041-26-000002","document":"wk-form4_1768008888.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804126000002/wk-form4_1768008888.xml","form_type":"4"}},{"id":1271744,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-12T22:00:31.000Z","date":"2025-02-06","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":2.2828,"value":45656.0,"ownership":{"direct":true},"balance_after":36629,"source":{"system":"sec-edgar","filing":"0001725160-25-000047","document":"wk-form4_1739397624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000047/wk-form4_1739397624.xml","form_type":"4"}},{"id":1281926,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T23:30:36.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":16629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":16629,"derivative":{"exercise_price":1.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":16629},"source":{"system":"sec-edgar","filing":"0001725160-25-000037","document":"wk-form4_1738798229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000037/wk-form4_1738798229.xml","form_type":"4"}},{"id":1281925,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-05T23:30:36.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":16629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":16629,"source":{"system":"sec-edgar","filing":"0001725160-25-000037","document":"wk-form4_1738798229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000037/wk-form4_1738798229.xml","form_type":"4"}},{"id":1345122,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T00:02:41.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":712650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over a four-year period as follows: 25% of the options will vest on November 13, 2025, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":712650,"derivative":{"exercise_price":3.66,"expiration_date":"2034-12-02","underlying":"Common Stock","underlying_shares":712650},"source":{"system":"sec-edgar","filing":"0001725160-24-000190","document":"wk-form4_1733270555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000190/wk-form4_1733270555.xml","form_type":"4"}},{"id":2502222,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:25:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":14.11,"expiration_date":"2030-11-12","underlying":"Common Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001104659-21-141741","document":"tm2133436-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141741/tm2133436-9_4seq1.xml","form_type":"4"}}]}